Thrombolytic therapy is the most commonly used reperfusion strategy after acute myocardial infarction. It is still unclear whether coronary angiography after thrombolysis should be available routinely for all patients after thrombolysis or targeted to specific groups. In this issue, Llevadot and colleagues present an analysis of practice patterns following thrombolysis for acute myocardial infarction using the InTime II dataset [1] . InTime II was a randomized trial of 15 078 patients enrolled from 855 hospitals comparing the effects of two thrombolytic agents, lanoteplase (nPA) and alteplast (tPA) on clinical outcomes. The results of InTime II showed that these two agents had very similar effects on mortality rates, but there was a suggestion that lanoteplase was associated with a higher rate of cerebral haemorrhage [2] . In the present analysis they compare rates of angiography and revascularization across three hospital groups: those with
Editorials 2049
cardiac catheterization facilities available 24 hours a day, those with the same facilities available during the day only, and those with no on-site catheterization facilities at all. Procedures were assigned to the admission hospital regardless of whether they were performed subsequently after inter-hospital transfer.
Pre-discharge angiography rates in the three groups were 57, 38 and 26%, respectively. The corresponding rates of percutaneous coronary intervention were 32, 17 and 15% and any revascularization (including coronary artery surgery) 37, 21 and 17%, respectively. Thirty-day all-cause mortality rates at centres with 24 hour, daytime-only and no catheterization facilities were 6·3, 6·6 and 7·0%, respectively (P for trend=0·11) and at 1 year, mortality rates were 9·5, 10·1 and 10·5% (P for trend=0·09). Rates of recurrent angina were significantly lower at 30 days in hospitals with any catheterization facility compared to those without, but rates of major bleeding were slightly higher. The authors conclude that the availability of catheterization facilities is the major determinant of whether a patient undergoes coronary angiography. They also observe that certain high risk groups like the elderly and those with prior myocardial infarction are less likely to undergo angiography, and there was no apparent association between outcomes and rates of angiography and revascularization.
How can we interpret these findings and can they help us in clinical practice? There are several methodological issues to discuss. These are retrospective analyses using a data set from a randomized trial. Patients in the study are treated as a cohort and stratified by the availability of cardiac catheterization facilities at the admitting hospital. Analyses of the frequency of cardiac catheterization, revascularization and clinical outcomes are presented using univariate and multivariate models. These analyses are not randomized and although superficial inspection of the major clinical characteristics of patients entering the different types of hospital look similar, there are likely to be biases when making comparisons across the hospital categories.
The absolute difference in rate of revascularization between hospitals with 24-hour facilities and those without was about 20%. This difference is probably not sufficient to influence important clinical outcomes such as death or recurrent myocardial infarction. The authors also point out that the beneficial effects of coronary revascularization may take some years to accrue and the 6-12 months follow-up in the study may not be sufficient to detect these benefits.
When differences in revascularization rates are modest (for example 20% or less) it becomes very difficult to detect early differences in clinical outcomes. Two studies which were able to detect differences were FRISC-II and DANAMI. In FRISC-II, a randomized trial of revascularization strategy compared to a conservative approach after unstable angina or myocardial infraction without ST segment elevation, the absolute difference in rates of revascularization at 10 days was 62% between the two groups [3] . The rates of the composite outcome of death or myocardial infarction at 6 months were significantly different in the revascularization group compared to the conservative group at 9·4 vs 12·1% (RR 0·78; 95% CI 0·62-0·98; P=0·031). The DANAMI study was a randomized trial of 1008 patients, comparing a conservative with an invasive strategy for patients with evidence of ischaemia after myocardial infarction [4] . The revascularization rate in the invasive arm was 82% compared to 15% in the conservative arm and after about 2·4 years of follow-up there was a significant reduction in the composite outcome of death, myocardial infarction and unstable angina.
Other recent observational registries also provide evidence of wide variations in the rates of angiography and revascularization between countries. The use of angiography in patients with myocardial infarction in the ENACT registry was 33% overall and ranged from 6 to 79% [5] . Rates of percutaneous coronary intervention were 23% overall, with a range from 7 to 62%. The range within a country was also wide for rates of angiography and coronary intervention, particularly with respect to the type of admitting hospital. At university hospitals the angiography and coronary intervention rates for all acute coronary syndrome patients were 49 and 31% and at community hospitals were 24 and 13%, respectively. Similarly, in the MITI registry of 12 331 patients admitted with acute myocardial infarction in Seattle between 1988 and 1994, coronary angiography and percutaneous intervention rates were 67 and 32% respectively in hospitals with a cardiac catheter laboratory and 39 and 13% in hospitals without [6] . Even with some methodological limitations, analyses from the study by Llevadot et al. can help us to identify important clinical problems and generate hypotheses for future investigation. Two issues are the inequality of access to cardiac catheterization and revascularization, and the appropriate use of invasive strategies for patients with failed reperfusion after thrombolysis. If the main driver for performing cardiac catheterization is the availability of facilities it implies that the criteria for performing the procedure are not standardized across a wide range of hospitals. For vulnerable patients, the probability of undergoing cardiac catheterization is largely dependent on which hospital they are taken to rather than their clinical need and prognosis. This supports the notion of a health care 'lottery' in under-resourced health care systems. Thus we need to implement more stringent criteria for determining who receives cardiac catheterization and their priority for this procedure irrespective of which hospital they present to. Finally we do not have the evidence base for supporting an approach for 'routine' cardiac catheterization and further randomized studies would be helpful including careful health economic evaluation of these resource intensive treatments.
A Although the majority of patients undergoing cardiac catheterization for the investigation of chest pain are men, those in whom normal coronary arteries are most frequently found are predominantly women of whom most are post-menopausal [1] [2] [3] . This observation, coupled with the evidence that oestrogens are vasoactive substances, a deficiency of which is associated with vasomotor instability and decreased arterial flow velocity, has led to the suggestion that oestrogens may play a central role in the pathogenesis of chest pain in post-menopausal patients with angina with normal coronary arteriograms [3] [4] [5] . This hypothesis is also supported by the symptomatic benefit derived from oestrogen replacement therapy in postmenopausal women with the syndrome and by the finding that hyperaemic vasodilator reserve, found to be impaired in women with angina with normal coronary arteriograms, is normalized by oestrogen replacement therapy [3, 6] . A significant 50% reduction in the frequency of episodes of chest pain in post-menopausal women with angina with normal coronary arteriograms when treated with oestrogen replacement therapy has been reported [6] . However, this beneficial effect upon chest pain is not coupled with any significant improvement in exercise time or changes in any of the variables assessed by either exercise testing or ambulatory ECG monitoring and suggestive of myocardial ischaemia. This indicates a dissociation between the beneficial effect upon symptoms and the results of cardiovascular assessment and shows that although angina with normal coronary arteriograms is likely to be heterogeneous with multiple pathogenetic components, the Editorials 2051
